Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or

Spark Therap (ONCE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,134,774
  • Shares Outstanding, K 38,413
  • Annual Sales, $ 64,730 K
  • Annual Income, $ -78,820 K
  • 60-Month Beta 2.48
  • Price/Sales 64.37
  • Price/Cash Flow N/A
  • Price/Book 9.31

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate -1.10
  • Number of Estimates 6
  • High Estimate -0.70
  • Low Estimate -1.38
  • Prior Year -1.25
  • Growth Rate Est. (year over year) +12.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
105.89 +1.67%
on 05/01/19
111.43 -3.38%
on 04/25/19
-2.96 (-2.68%)
since 04/18/19
3-Month
49.06 +119.45%
on 02/21/19
114.20 -5.73%
on 03/12/19
+56.77 (+111.55%)
since 02/20/19
52-Week
34.53 +211.79%
on 12/26/18
114.20 -5.73%
on 03/12/19
+30.95 (+40.35%)
since 05/18/18

Most Recent Stories

More News
Roche and Spark Therapeutics, Inc. announce expected refiling date of Premerger Notification and Report Forms under the HSR Act and extension of tender offer for shares of Spark Therapeutics, Inc.

F. Hoffmann-La Roche Ltd / Roche and Spark Therapeutics, Inc. announce expected refiling date of Premerger Notification and Report Forms under the HSR Act and extension of tender offer for shares of...

ONCE : 107.66 (+0.02%)
Will Spark Therapeutics (ONCE) Report Negative Q1 Earnings? What You Should Know

Spark Therapeutics (ONCE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ONCE : 107.66 (+0.02%)
New Gene Therapies Hold Out Promise for Patients

Gene therapies are gaining growing attention within the medical sector.

TROV : 3.07 (-0.32%)
ONCE : 107.66 (+0.02%)
NVS : 82.01 (-0.83%)
DYAI : 3.90 (-5.80%)
Roche and Spark Therapeutics, Inc. announce withdrawal and refiling of Premerger Notification and Report Form under the HSR Act and extension of tender offer for shares of Spark Therapeutics, Inc.

F. Hoffmann-La Roche Ltd / Roche and Spark Therapeutics, Inc. announce withdrawal and refiling of Premerger Notification and Report Form under the HSR Act and extension of tender offer for shares of...

ONCE : 107.66 (+0.02%)
Spark Therapeutics CEO and Former Merck President to Keynote Veeva Commercial & Medical Summit

Veeva Systems (NYSE:VEEV) today announced that Adam H. Schechter, former president of Global Human Health at Merck & Co., Inc. and now advisor to the chief executive officer, and Jeffrey...

ONCE : 107.66 (+0.02%)
MRK : 78.88 (+0.20%)
VEEV : 140.66 (-0.78%)
Spark Therapeutics Announces Sponsorship of Believe Limited's First-Ever Science Fair for the Hemophilia Community at 2019 National Hemophilia Foundation's Bleeding Disorders Conference

Spark Therapeutics (NASDAQ: ONCE), a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, announced today that it will serve as the inaugural...

ONCE : 107.66 (+0.02%)
Spark Therapeutics (ONCE) Merger Class Action Lawsuit: Halper Sadeh LLP Announces Filing of Shareholder Class Action Lawsuit Against Spark Therapeutics, Inc. Concerning Its Proposed Merger With Roche Holdings, Inc. - ONCE

Halper Sadeh LLP, a global investor rights law firm, announces the filing of a shareholder class action lawsuit against Spark Therapeutics, Inc. ("Spark" or the "Company") (NASDAQ: ONCE) in connection...

ONCE : 107.66 (+0.02%)
Ophthotech Gets Rights to Gene Therapy for BEST Disease

Ophthotech (OPHT) obtains development/commercialization rights to AAV gene-therapy program for BEST1-related retinal diseases from Penn and UFRF.

ONCE : 107.66 (+0.02%)
OPHT : 1.39 (-0.71%)
NVS : 82.01 (-0.83%)
RHHBY : 33.1100 (+0.82%)
Biotechnology Market on a Tear: 5 ETFs in Spotlight

Increasing M&A deals, growing AI dominance and favorable regulatory tidings continue to accelerate the biotech market. Accordingly, ETFs with exposure to the sector continue to shine.

BBP : 38.90 (-2.20%)
SBIO : 32.87 (-2.03%)
ARKG : 30.62 (-1.35%)
ONCE : 107.66 (+0.02%)
ILMN : 300.59 (-2.29%)
JNJ : 138.42 (-0.14%)
LLY : 116.23 (+0.19%)
NVS : 82.01 (-0.83%)
RHHBY : 33.1100 (+0.82%)
PFE : 41.59 (+0.29%)
XBI : 80.77 (-2.17%)
BTEC : 32.77 (+2.53%)
Biotechnology Market on a Tear: 5 ETFs in Spotlight

Increasing M&A deals, growing AI dominance and favorable regulatory tidings continue to accelerate the biotech market. Accordingly, ETFs with exposure to the sector continue to shine.

BBP : 38.90 (-2.20%)
SBIO : 32.87 (-2.03%)
ARKG : 30.62 (-1.35%)
ONCE : 107.66 (+0.02%)
ILMN : 300.59 (-2.29%)
JNJ : 138.42 (-0.14%)
LLY : 116.23 (+0.19%)
NVS : 82.01 (-0.83%)
RHHBY : 33.1100 (+0.82%)
PFE : 41.59 (+0.29%)
XBI : 80.77 (-2.17%)
BTEC : 32.77 (+2.53%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum. Long term indicators are in flux.

See More Share

Trade ONCE with:

Business Summary

Spark Therapeutics, Inc. offers gene therapy. The Company's product candidate consist of SPK-RPE65, SPK-CHM, SPK-FIX which are in different clinical phases, for the treatment of additional blinding conditions, hematologic disorders and neurodegenerative diseases. Spark Therapeutics, Inc. is based in...

See More

Key Turning Points

2nd Resistance Point 108.85
1st Resistance Point 108.26
Last Price 107.66
1st Support Level 106.86
2nd Support Level 106.05

See More

52-Week High 114.20
Last Price 107.66
Fibonacci 61.8% 83.77
Fibonacci 50% 74.36
Fibonacci 38.2% 64.96
52-Week Low 34.53

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar